Quick Answer
Raphael Pharmaceutical Inc. reported R&D Expense of $631.0 thousand for fiscal year 2025.
Raphael Pharmaceutical Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $631.0K | -18.7% |
| 2024 | $776.0K | +36.4% |
| 2023 | $569.0K | -51.7% |
| 2022 | $1.18M | +51.8% |
| 2021 | $776.0K | +68.3% |
| 2020 | $461.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $73.0K | -54.9% | -48.2% |
| June 30, 2025 | $141.0K | +487.5% | +95.8% |
| March 31, 2025 | $72.0K | -81.0% | -55.6% |
| September 30, 2024 | $162.0K | -68.2% | +575.0% |
| June 30, 2024 | $24.0K | -91.8% | -93.7% |
| March 31, 2024 | $379.0K | +232.5% | -25.7% |
| September 30, 2023 | $510.0K | +53.6% | +74.1% |
| June 30, 2023 | $293.0K | +248.8% | +157.0% |
- Raphael Pharmaceutical Inc. showed a decrease of -18.7% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Raphael Pharmaceutical Inc.’s r&d expense has grown by 36.9% (from $461.0 thousand to $631.0 thousand).
- The most recent figure is from Raphael Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: